Blackstone's $2.25 billion sale of clinical research organization Precision Medicine Group to McKesson looked like a low-teens EBITDA deal — but it sold on earnings closer to $100 million, versus the $200 million initially marketed, Axios Pro has learned.
Why it matters: Private equity's clinical trial site management auction pipeline is stacked, and the market is hungry for reliable comparables.
